Alglucerase
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692001 |
| ATC code | A16AB01 (WHO) |
| Pharmacokinetic data | |
| Biological half-life | 3.6–10.4 min |
| Identifiers | |
| |
| CAS Number |
37228-64-1  |
| DrugBank |
DB00088 |
| ChemSpider | none |
| UNII |
27T56C7KK0 |
| KEGG |
D09675 |
| ChEMBL |
CHEMBL1201633  |
| Chemical and physical data | |
| Formula | C2532H3854N672O711S16 |
| Molar mass | 55597.4 g/mol |
| (what is this?) (verify) | |
Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.[1]
Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug appoved as an enzyme replacement therapy.[1]
It was approved by the FDA in 1991.[2] It has been withdrawn from the market[3][4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture[1] (see imiglucerase).
References
- 1 2 3 4 Deegan, PB; Cox, TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Des Devel Ther. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106
. PMID 22563238. - ↑ World Health Organization. Regulatory Matters WHO Drug Information 5:3) 1991. p 123
- ↑ Aetna. Last reviewed 8 August 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
- ↑ FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List